Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.59 |
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | GMNN | O75496 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL29723505 | 0.98 | KDM4E (0.61) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL3960 | 0.98 | KDM4E (0.61) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL1661720 | 0.98 | KDM4E (0.61) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL29367714 | 0.97 | KDM4E (0.59) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL9879420 | 0.97 | KDM4E (0.59) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL9879191 | 0.97 | KDM4E (0.59) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL29521813 | 0.97 | KDM4E (0.59) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL9878595 | 0.97 | KDM4E (0.59) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL3468 | 0.97 | KDM4E (0.59) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| Salicylic Acid SCHEMBL9647802 | 0.97 | KDM4E (0.59) | KDM4EHPGDALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4397 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| WO-2025081174-A1 | COMBINATION TREATMENT OF AUTOIMMUNE DISORDERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-04-17 | — | — | WO | claimed |
| CN-119792640-A | Filler composition, preparation method and application thereof | 渼颜空间(河北)生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| CN-119236172-A | Injection filler and preparation method and application thereof | 渼颜空间生物科技(吉林)有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119212681-A | Method for preparing 3-D printed pharmaceutical products | 百时美施贵宝公司 | 2024-12-27 | — | — | CN | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| CN-118557622-A | A Chinese medicinal composition comprising radix Platycodi, glycyrrhrizae radix, fructus Phyllanthi and fructus Canarii albi and its antiinflammatory application | 嘉兴复道致德医疗科技有限公司 | 2024-08-30 | — | — | CN | claimed |
| US-20030077308-A1 | Topical compositions for veterinary uses | TEND SKIN COMPANY | 2003-04-24 | — | — | US | claimed |
| EP-1296929-A2 | MODIFIED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | Medinox, Inc. (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2002098404-A1 | TOPICAL COMPOSITIONS FOR VETERINARY USES | TENDSKIN COMPANY (US) | 2002-12-12 | — | — | WO | claimed |
| US-6429223-B1 | Modified forms of pharmacologically active agents and uses therefor | MEDINOX, INC. | 2002-08-06 | — | — | US | claimed |
| US-6355666-B1 | ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | MEDINOX, INC. | 2002-03-12 | — | — | US | claimed |
| WO-2002000167-A2 | MODIFIED FORMS OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 2002-01-03 | — | — | WO | claimed |
| WO-2001093680-A1 | PROTECTED FORMS OF A COMBINATION OF PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR | MEDINOX, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-6306842-B1 | COMPOUND OF NONSTEROID ANTIINFLAMMATORY AGENT, SPACER AND COX-2 INHIBITOR | MEDINOX, INC. | 2001-10-23 | — | — | US | claimed |
| CN-1073859-A | Regulate the compositions of wrinkle of skin and/or atrophoderma | RICHARDSON VICKS INC (US) | 1993-07-07 | — | — | CN | claimed |
| US-5043168-A | Nonhygroscopic, antiarthritis agent, analgesic | SIDMAK LABORATORIES, INC. (US) | 1991-08-27 | — | — | US | claimed |